Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • المصدر:
    Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int. 2020 Jun;97(6):1287-1296. doi: 10.1016/j.kint.2020.01.035. Epub 2020 Mar 6. Erratum In: Kidney Int. 2020 Dec;98(6):1621. Kidney Int. 2021 May;99(5):1244.
    A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
  • الدخول الالكتروني :
    https://clinicaltrials.gov/ct2/show/NCT03131219
  • معلومة اضافية
    • الدخول الالكتروني :
      https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=ALXN1210-aHUS-312&attachmentIdentifier=5ae2d7b1-7696-4a07-bb98-7e5aeac5849c&fileName=ALXN1210-aHUS-312_EOS_Addendum_Synopsis_Redacted.pdf&versionIdentifier=